Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway

Diabetic nephropathy (DN) is the leading cause of end-stage failure of the kidney, but the efficacy of current strategies available for the prevention of DN remains unsatisfactory. The purpose of this study was to assess whether sitagliptin (SIT) has therapeutic potential for prevention of DN and to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Mol Med
Glavni autori: Wang, Dongdong, Zhang, Guanying, Chen, Xiao, Wei, Tong, Liu, Chenxu, Chen, Chun, Gong, Yinhan, Wei, Qunli
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2018
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5846674/
https://ncbi.nlm.nih.gov/pubmed/29484381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijmm.2018.3504
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items